# Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®

> **NCT03061838** · PHASE1 · TERMINATED · sponsor: **Biointegrator LLC** · enrollment: 8 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MabThera®
- **DRUG:** Ritumax®

## Key facts

- **NCT ID:** NCT03061838
- **Lead sponsor:** Biointegrator LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-27
- **Primary completion:** 2018-03-14
- **Final completion:** 2018-03-14
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061838, "Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03061838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*